Tadalafil
Product Images NDC 70934-473
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70934-473). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
84125597 9492 4bb8 Bbba 6d56a874e856 01
84125597 9492 4bb8 Bbba 6d56a874e856 02
84125597 9492 4bb8 Bbba 6d56a874e856 03
84125597 9492 4bb8 Bbba 6d56a874e856 04
84125597 9492 4bb8 Bbba 6d56a874e856 05
84125597 9492 4bb8 Bbba 6d56a874e856 06
84125597 9492 4bb8 Bbba 6d56a874e856 07
The text provides information about the change from baseline in IPSS total score after treatment with Tadalafil 5mg as compared to Placebo. The results show that the change is statistically significant (p<0.01) with Tadalafil 5mg being more effective in reducing IPSS total score than placebo. The duration of treatment in weeks is not available.*
84125597 9492 4bb8 Bbba 6d56a874e856 08
84125597 9492 4bb8 Bbba 6d56a874e856 09
This text describes a graph or chart that displays the change in IPSS (International Prostate Symptom Score) total score over a 12-week treatment period. The treatment options compared are Tadalafil 5mg and Placebo. The asterisk indicates that there is a statistically significant difference between Tadalafil and Placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.